Compare Garmin Ltd. (GRMN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs TG Therapeutics Inc — how do they compare? Garmin Ltd. trades at $268.82 (market cap $51.77B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: Garmin Ltd. is far larger — about 6.3× TG Therapeutics Inc's market cap, and Garmin Ltd. pays a 1.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and TG Therapeutics Inc for 16 Days on average.
| GRMN | TGTX | |
|---|---|---|
Market Cap | $51.77B | $8.16B |
Volume | 961,398 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $313.16 | $59.06 |
52-Week Low | $187.10 | $26.94 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $49.28B | $8.37B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.51, down 2.77% today, amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income show steady growth, reaching $7.25B and $1.66B in 2025, respectively, supported by strong profitability margins. Recent news highlights product innovations and industry awards, reinforcing its market position.
The outlook remains positive given earnings momentum and a consensus price target of $320.25, implying significant upside. However, high valuation ratios and bearish technical indicators pose near-term risks. Investors should weigh strong fundamentals against potential volatility and competitive pressures in the consumer electronics space.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
